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ABSTRACT
Purpose: The determination of prognosis in patients with renal cell carcinoma (RCC) is based, classically, on stage and 
histopathological aspects. The metastatic disease develops in one third of patients after surgery, even in localized tumors. 
There are few options for treating those patients, and even the new target designed drugs have shown low rates of suc-
cess in controlling disease progression. Few studies used high throughput genomic analysis in renal cell carcinoma for 
determination of prognosis. This study is focused on the identification of gene expression signatures in tissues of low-risk, 
high-risk and metastatic RCC clear cell type (RCC-CCT).
Materials and Methods: We analyzed the expression of approximately 55,000 distinct transcripts using the Whole Ge-
nome microarray platform hybridized with RNA extracted from 19 patients submitted to surgery to treat RCC-CCT with 
different clinical outcomes. They were divided into three groups (1) low risk, characterized by pT1, Fuhrman grade 1 or 
2, no microvascular invasion RCC; (2) high risk, pT2-3, Fuhrman grade 3 or 4 with, necrosis and microvascular invasion 
present and (3) metastatic RCC-CCT. Normal renal tissue was used as control.
Results: After comparison of differentially expressed genes among low-risk, high-risk and metastatic groups, we identified 
a group of common genes characterizing metastatic disease. Among them Interleukin-8 and Heat shock protein 70 were 
over-expressed in metastasis and validated by real-time polymerase chain reaction.
Conclusion: These findings can be used as a starting point to generate molecular markers of RCC-CCT as well as a target 
for the development of innovative therapies.
 
Key words:  carcinoma, renal cell; microarray analysis; neoplasm metastasis; oncogenes; Interleukin 8, heat-shock pro-
tein; gene expression profiling
Int Braz J Urol.  2010; 36: 410-9
INTRODUCTION
 Renal cell carcinoma (RCC) accounts for ap-
proximately 5% of all malignancies and is considered 
the most lethal urological cancer (1,2). At early stages, 
it can be curable by surgical resection, but no effective 
 Clinical Urology  
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treatment option is available for patients at advanced 
stage. Up to 30% of the cases have metastasis at initial 
diagnosis and 30% of initially organ-confined cases 
will develop metastases during follow-up (3,4).
 Treatment options available for patients with 
metastatic disease are very limited and currently tar-
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get therapy has been developed based on molecular 
peculiarities of RCC. Transcriptional profiling has 
also emerged as a powerful approach to identify the 
molecular mechanism underlying renal carcinogen-
esis and in predicting clinical outcomes (5). Gene 
expression profile may help to identify new bio-
markers of aggressiveness and prognosis, selecting 
patients who could benefit from ancillary therapy. 
Microarray-based expression profiles have become 
a standard methodology in any high-throughput 
analysis.
 There are few reported studies of gene ex-
pression in RCC clear cell type (RCC-CCT) which 
have assessed prognosis. Most of these studies used 
different subtypes of RCC, which is inappropriate 
since they have different carcinogenesis pathways 
and clinical behavior (6-9).
 This study is focused on the identification 
of gene expression signatures in tissues of low-risk, 
high-risk and metastatic RCC-CCT. It was carried out 
using the Whole Genome Microarray platform, which 
simultaneously evaluates the mRNA level of 55.000 
transcripts ESTs (Expressed Sequences Tags). The 
resulting expression panel is a statistical representa-
tion of physiological responses occurring in the finely 
tuned transcriptional regulation.
MATERIALS AND METHODS
Patients and Tumor Samples
 Tissue samples of RCC-CCT obtained from 
the surgical specimens extracted from open nephrec-
tomy of 19 patients were evaluated. The patients 
were divided in three groups: 1) Low risk RCC-CCT 
(Fuhrman nuclear grade 1 or 2, pT1 and no microvas-
cular neoplastic invasion or tumor necrosis); 2) High 
risk RCC-CCT (Fuhrman nuclear grade 3 or 4 all 
staged pT3, all tumors had necrosis and microvascular 
neoplastic invasion), and 3) Metastatic RCC-CCT. 
Group 1 was composed of five men and two women 
submitted to tumor resection or partial nephrectomy; 
mean age  53.3 years-old (median 53, range 48-56), 
pT1, mean tumor size of 3.7 cm (median 3, range 1.8-
6.5), Fuhrman grade 1 or 2, no microvascular invasion 
or necrosis. Group 2 was constituted of four males 
and one female submitted to radical nephrectomy, 
mean age 60 years-old (median 65, range 39-73), T2-3 
mean tumor size of 8.2 cm (median 9, range 3.9-11), 
Fuhrman grade 3 or 4 with necrosis and microvascu-
lar invasion present. Group 3 was characterized by 
seven patients with metastatic RCC, (six males and 
one female) mean age  57.7 years-old (median 60, 
range 39-69) extracted from metastatic specimens 
of the primary tumor. The control group was a pool 
of normal cortical renal tissue from 4 patients with 
chronic kidney infections.
 Surgical specimens were immediately sent to 
surgical pathology laboratory, and frozen at -170°C 
in liquid nitrogen maximum after 15 minutes. Insti-
tutional Review Board approved the protocol and 
informed consent was obtained from all patients.
Microarray Experiment
 Frozen tissue samples were mechanically 
disrupted in liquid nitrogen and total RNA was 
extracted with Trizol reagent according to a pre-
established protocol (Invitrogen Life Technologies, 
Carlsbad, CA). For each of the three group described 
above, 10 μg of total RNA from each tissue sample 
was distributed between three pools. Double-strand-
ed cDNAs were synthesized from 10 μg of total 
RNA using SuperScript Choice double-stranded 
cDNA synthesis kit from Invitrogen following the 
manufacturer’s protocol. cDNAs were purified by 
phenol/chloroform extraction and ethanol precipita-
tion. Biotin-labeled cRNAs were synthesized by an 
in vitro transcription reaction using the BioArray 
HighYield RNA Transcript Labeling Kit (Enzo Di-
agnostics, Farmingdale, NY). cRNAs were purified 
from the in vitro transcription reaction using RNeasy 
Mini kit (Qiagen, Valencia, CA). Biotin-labeled 
cRNA was generated from each sample following 
the manufacturer’s protocol. cRNA was hybridized 
onto CodeLink® whole genome microarray slides, 
washed and hybridized cRNA species were detected 
using Cy5-Streptavidin (Amersham, UK). Slides 
were scanned using GenePix Personal 4100A Mi-
croarray Scanner (Axon Instruments) and analyzed 
with CodeLink® Expression Analysis software.
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Microarray Statistical Analysis
 Statistical analysis of the CodeLink® micro-
array slides was performed using the publicly avail-
able R statistical environment (http://www.r-project.
org). The normalization and background correction 
were performed using the LIMMA package (Linear 
Models for Microarray Analysis) (10); a part of the 
Bioconductor Microarray Suite (www.bioconductor.
org).The background noise was corrected using the 
normEXP algorithm and the values were normalized 
by a cyclic LOESS smooth function with a hundred of 
interactions using the a adjusting parameter of 1.0.
 The normalized data were organized lo-
cally and using a Perl (http://www.perl.org) script 
we determined the minimum variation (fold change) 
threshold accepted as been significant. Datasets of 
each histological group were compared in a pairwise 
fashion. For each comparison performed, the fold 
change for a given spot was calculated. These values 
were distributed and the mean and standard devia-
tion (SD) values of expression variation of all genes 
were determined. A gene was accepted as differently 
expressed if its expression variation was greater than 
the mean plus one SD or lower than the mean minus 
one SD. Finally, only genes accepted as significant on 
all comparisons were selected. This group of candi-
date genes were identified and organized locally. The 
gene lists were numerically sorted and the top UP and 
DOWN regulated genes were determined for each 
comparison. Functional classification of these genes 
was performed using Gene Ontology Consortium 
2000.
Quantitative Real-Time PCR and Gene 
Expression
 For qRT-PCR gene expression validation 
we evaluated 7 patients from group 1 (Low risk 
RCC-CCT), 5 patients from group 2 (High risk 
RCC-CCT) and 7 patients from group 3 (Metastatic 
RCC-CCT).
 Total RNA extraction was performed using 
Trizol (Invitrogen Life Technologies, Carlsbad, CA) 
as mentioned previously. Pureness and concentra-
tion of RNA were measured in a spectrophotometer 
(260/280 nM), and integrity was verified in an Agilent 
2100 bioanalyzer (Agilent Technologies, Santa Clara, 
CA, USA). Synthesis of cDNA was performed from 
at least 5μg of total RNA with the enzyme M-MLV 
reverse transcriptase and random primers (Invitrogen 
Life Technologies, Carlsbad, CA, USA). The reac-
tions were incubated at 65°C for 5 min followed by 
37°C for 1h and finally 95°C for 5 min. The cDNA 
reactions were diluted to 100 μL in nuclease-free 
water (Invitrogen Life Technologies, Carlsbad, CA, 
USA) and stored at -20°C until further use.
 The expression of two genes was analyzed 
from cDNA through the qRT-PCR technology in the 
Abi7500 platform using the TaqMan® protocol (Ap-
plied Biosystems). TaqMan® Endogenous Control 
Assay ID is Hs99999907-m1 (B2M) and Gene Ex-
pression Assay IDs are Hs00359147-s1 (HSPA1A and 
HSPA1B) and Hs00174103-m1 Interleukin 8 (IL-8). 
cDNA (2μL) from each tumor sample was added to 
a PCR reaction mix containing 1X TaqMan® Uni-
versal PCR Master Mix, AmpErase® UNG and 1 μL 
Endogenous Control Assay or Gene Expression Assay 
(Applied Biosystems) in a 20 μL reaction volume. The 
cycling conditions were 50ºC for 2 min, 95ºC for 10 
min and 40 cycles of 95ºC for 15 sec and 60ºC for 
1 min. The ΔΔCT method was used to calculate the 
relative expression of the two target genes and the 
fold change in gene expression in tumor relative to 
normal tissues determined by 2-ΔΔCT (11).
RESULTS
 Several analyses were performed to identify 
the differentially expressed genes among the three 
groups of patients and controls. A significant propor-
tion of differently expressed genes were identified 
in each comparison tested, the microarray plots are 
shown in Figure-1. As regards to low risk RCC-CCT 
(Figure-1A), there was little dispersion of the features 
referring to the differences in genetic expression, 
which tends to be distributed in a straight line, next 
to zero. Therefore, low-risk tumors showed insig-
nificant alterations in their genetic expression when 
compared to normal tissues. High-risk and metastatic 
tumors (Figures 1B and C) have shown a significant 
increase in the proportion of differently expression 
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genes. This could reflect the expected disequilibrium 
in gene regulation of metastatic or prone to be tis-
sues. The MA plots were used as quality control of 
the microarray experiments, since it is expected that 
variations in global gene expression tend to be subtle 
and any variation of linearity can reflect physiologi-
cal/pathological adaptations.
 To identify the most important genes in the 
progression of RCC-CCT we selected the 50 most 
differentially expressed genes in each comparative 
group. After comparison among the differentially ex-
pressed genes in the low-risk, high-risk and metastatic 
groups, we identified a group of common genes, which 
presented either increase or reduction in their expres-
sion, from the low risk to the metastatic state. These 
genes are shown in Tables 1 and 2. When compared to 
the low-risk and high-risk groups, nine over-expressed 
and eleven under-expressed genes were found in the 
metastatic group. The differentially expressed genes 
in each comparison were functionally classified using 
the GO (Gene Ontology) database (Figure-2).
 Two genes, IL-8 and HSP70, which had pre-
sented greater expression differences, were chosen to be 
validated by qRT-PCR. The validation was performed 
in the three groups mentioned as low-risk (LR), high-
risk (HR) and metastatic (M) renal cell carcinomas. As 
seen in Figure-3, over expression of HSP70 and IL-8 
was present in 100% (13/13) and 77% (10/13) respec-
tively of metastatic carcinoma cases tested. The graph 
shows quantitative expression of genes in RCC tissue 
relative to normal cells. Fold change in gene expres-
sion was calculated using the ΔΔCT method (QRel = 
2-ΔΔCT). Kruskal-Wallis test showed significant dif-
ference between metastatic and the other two groups 
(p = 0.0002). This pattern was significantly different 
from high-risk and low-risk carcinomas.
COMMENTS
 Description of thousands of genomic se-
quences along with the technological development 
to identify the gene expression profile on a large 
scale has provided a remarkable improvement in the 
analysis of carcinogenesis process. This improved 
knowledge has had an impact on the latest advances 
regarding classification of neoplasias, identification 
of new diagnostic and prognostic markers, and find-
ing of possible therapeutic targets. Until recently, the 
studies that evaluated genetic expression through the 
Figure 1 – Representation of gene expression variation in dif-
ferent ranges of intensity (MA-plot) between (A) normal vs. low-
risk, (B) normal vs. high-risk, and (C) normal vs. metastatic 
genes.
A
B
C
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microarray technique in RCC had focused particularly 
on the description of genes for diagnostic molecular 
classification (6). The purpose of our research was the 
identification of gene expression profiles related to 
known anatomopathological parameters that are cor-
related to the prognosis (12). These genetic expression 
profiles can help to describe a comprehensible pattern 
via RCC progression and metastatization. Among the 
genes identified in our study the most important ones 
are IL-8, and the heat shock protein (HSP-70) genes, 
which are closely linked to the known carcinogenesis 
way of the clear cell carcinoma.
Table 1 – Genes with lower expression from Low-risk to metastatic stage.
Abbreviation
Official/GI*
Identification
CodeLink® Gene Identification
gi40578461 12878 EST- atypical PKC isotype-specific interacting protein long variant mRNA
C7 16412 complement component 7 (C7)
FCGBP 16152 Fc fragment of IgG binding protein
PRAP1 46920 proline-rich acidic protein 1
PCP4 19612 Purkinje cell protein 4 (PCP4)
gi52793583 24985 EST-QV4-BN0090-210400-182-h09 BN0090 Homo sapiens cDNA
gi3870266 38798 EST-qz33c05x1 NCI_CGAP_Kid11 cDNA clone IMAGE:2028680 3’ similar to gb:X02747 FRUCTOSE-BISPHOSPHATE ALDOLASE B
WFDCD2 20765 WAP four-disulfide core domain 2 transcript variant 1
gi1401452 23196 EST-zh66h10s1 Soares_fetal_liver_spleen_1NFLS_S1 cDNA clone IM-AGE:417091 3’
*GI = genomic identification according to National Institutes of Health data bank. (http://www.ncbi.nlm.nih.gov)
Table 2 – Genes with higher expression from low-risk to metastatic stage.
Abbreviation 
Official/GI*
Identification
CodeLink® Gene Identification
gi22685430 34169 AGENCOURT_7932449 NIH_MGC_72 cDNA clone IMAGE:6156942 5’
R39367 11050 clone 24734 mRNA sequence
DUSP2 16648 dual specificity phosphatase 2
HSPA1A 39816 heat shock 70kDa protein 1A
HSPA1B 50162 heat shock 70kDa protein 1B
gi66255625 49424 EST-hypothetical protein LOC90637
IL8 24261 interleukin 8
- 36561 EST-mRNA; cDNA DKFZp667A182 (from clone DKFZp667A182)
UBC 6469 ubiquitin C
gi5863270 45082 EST-UI-H-BI0-aai-f-11-0-UIs1 NCI_CGAP_Sub1 cDNA clone IM-AGE:2709644 3’
gi2077388 29444 EST-zu07b03.r1 Soares_testis_NHT cDNA clone IMAGE:731117 5’ similar to contains MER30.t2 MER30 repetitive element
*GI = genomic identification according to National Institutes of Health data bank. (http://www.ncbi.nlm.nih.gov)
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 The gene profiles of the high-risk and meta-
static disease are quite similar, and this was described 
by Jones et al. (7) These authors, studying clear cell 
type RCC, identified a similar profile of genetic ex-
pression among both locally advanced and metastatic 
tumors, which was named metastatic signature. Kosari 
et al. (9) in a study quite similar to ours, also identified 
genes expressed in both aggressive and metastatic 
carcinomas.
 In recent years, the analysis of the gene 
expression profile on a  large scale has been widely 
used to define genetic expression patterns that can 
be related to neoplasia aggressiveness (13). Current 
studies on RCC have sought the identification of 
new prognostic markers. By studying 16 RCCs in a 
platform comprising 21,632 genes, (6) a correlation 
between the histological and genetic classifications in 
14 renal tumors. Jones et al. was identified. (7), study-
ing 65 RCC (23 CCC, 13 papillary, 7 chromophobes, 
12 oncocytomas) and 24 normal renal tissues defined 
a genetic profile associated with the development 
of metastasis, based on a platform of 22,283 genes 
(Affymetrix). Liou et al. (8) studied six RCCs and 
compared the differentiated genic expression with 
six normal renal tissues. By using a platform of 7,129 
genes (Affymetrics), they were able to demonstrate 
that 25% of genes are differentially expressed and 
among them, an over expression of adhesion mol-
ecules (laminin A and fibronectin) which would act 
in the progression of the neoplasia.
 The membrane receptors, like the epidermal 
growth factor receptor (EGFR), were poorly ex-
pressed in the initial RCC, as pT1a tumors; however, 
its overexpression was correlated with an increase in 
the tumor stage. These transmembrane glycoproteins 
interact with tyrosine kinase and promote invasion, 
metastasis and expression of biomarkers (14). Many 
target drugs have been studied in the attempt to inhibit 
cellular events acting directly on these receptors. Pres-
ently, tyrosine kinase inhibitory drugs have shown 
Figure 2 – Functional classes of overexpressed genes when comparing  high-risk tumors to low-risk tumors.
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promising results in cases of metastatic RCC, thus 
pointing to more reasonable expectations of disease 
control than isolated immunotherapy (15).
 The VHL gene is responsible for the codi-
fication of a protein, which is part of the elongin B 
and C complex, whose function is the degradation of 
the hypoxia-induced factor (HIF-1). This factor is an 
upregulator of the tyrosine kinase VEGFR receptor, 
that is overexpressed in RCCs. VEGFR regulates the 
hypervascular characteristic of RCC (16,17), which 
has already been the target for the development of 
inhibitory molecules and antibodies for therapeutic 
use. Both familiar and sporadic RCCs are related to 
mutation and/or loss of VHL gene, resulting in non-
formation of the elongin B and C complex and HIF-1 
accumulation. HIF-1 induces translation of genes 
related to angiogenesis, favoring the carcinogenesis. 
The VHL suppressor gene mutations are responsible 
for the VHL syndrome. The mutated gene is found in 
75% of sporadic RCC cases (18). It is believed that 
the tumor necrosis factor alpha (TNF-α) contributes to 
the VHL gene suppressive function (19); in our study, 
this gene was overexpressed in the low-risk cases in 
relation to the normal ones, validating Caldwell’s 
theory.
 Clear renal cell carcinoma occurs in approxi-
mately 80% of RCC cases, and a great deal of research 
shows different gene groups - either underexpressed 
or overexpressed - without significant intersections 
among the various studies. These discrepancies prob-
ably occur due to different criteria in the selection of 
the altered genes and the use of different microarray 
platforms with distinct anchored markers. Another 
aspect of criticism in any microarray analysis is the 
improper collection of neoplastic tissue and loss of 
cellular lineage in tumors, which are mostly hetero-
geneous (14).
 Using qRT-PCR we were able to validate 
the overexpression of IL-8 and HSP-70 in metastatic 
RCC-CCT. HSP is expressed by cells under pathologi-
cal and physiological conditions; its most important 
functions include homeostasis, apoptosis, and also a 
relevant role in antigenicity mediated by T cells (20). 
HSP27 and 72 overexpression are clinically relevant 
(21), particularly HSP27 overexpression in CCR when 
compared to normal renal cells (22). Conversely, in 
our study HSP70 1A and 1B were overexpressed in 
metastatic cases in relation to low-risk and high-risk 
cases. The HSP 70 is considered one of the most 
powerful stimulants to human immune response 
and the structure and function of these proteins and 
their relation with immunity have been extensively 
investigated (23). HSP is an integral component of 
HIF and this interaction induces HSP overexpres-
sion. Drug-oriented actions inhibiting the HIF-HSP 
complex might exert an inhibitory potential over this 
important carcinogenesis mechanism; it is necessary, 
however, to distinguish the effects of the HSP family 
members (23).
 IL-8 is over expressed by tumors and has 
been related to angiogenesis, mitotic activity and 
metastatization (24). Yoshida et al. (25) showed IL-8 
expression in breast, ovary, pancreas and prostate car-
cinoma related to higher stage and tumor progression. 
Figure 3 – Box-and-whisker plots of HSP70 and IL-8 expression in low-risk (LR), high-risk (HR) and metastatic (M) renal cell 
carcinoma.
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It regulates metalloproteinases 2 and 9 promoting 
stromal infiltration and angiogenesis facilitating the 
metastatic progression.
 Based on carefully analyzed molecular events 
in RCC, the benefits of individualized therapies will 
become prominent in the near future. However, con-
sidering that genetic alterations in cancer progression 
are complex and frequently imply multiple paths, the 
combination of new target-drugs for particular genes 
involved in each RCC histological subtype will be 
necessary.
CONCLUSIONS
 Distinct gene expression profiles of low-risk, 
high-risk and metastatic RCCs were demonstrated, 
with emphasis on the progressive higher expression of 
the HSP 70 and IL-8 genes from Low-risk to metastatic 
stage. Based on our findings, it is possible to suggest 
these genes as starting points for prognostic molecular 
markers and/or targets for specific therapies.
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EDITORIAL COMMENT
 In this nicely written paper by Dall’Oglio et 
al., the gene expression profile of clear cell type re-
nal cell carcinoma (RCC) was conducted to identify 
the functional genes selectively expressed in low-, 
high-, and metastatic RCC patients. Although sev-
eral groups have conducted tissue microarray stud-
ies focusing on RCC (1-4), the present study has 
several merits; firstly, the authors have evaluated 
the gene expression profiles of a uniform patient 
cohort (i.e. those with clear cell histology) remov-
ing study population heterogeneity as a confounding 
variable, secondly, the authors have stratified their 
study population according to risk of progression 
whereby allowing to better define the gene expres-
sion profiles of these prognostic subsets. It is clear 
to me that although major strides have been made in 
the systemic therapy of metastatic RCC (i.e. tyrosine 
kinase inhibitors, mTOR inhibitors), it remains clini-
cally disappointing that a partial response or disease 
stability for a typical period of several months is 
noted in responders to these systemic agents. The 
treatment panacea for metastatic RCC (i.e. complete 
response rendering patients disease-free) will only 
likely come with a better understanding of the genet-
ic and mechanistic pathways underlying this hetero-
geneous malignancy. Studies such as this will likely 
lead to a more personalized therapeutic approach to 
patients in which the genetic alterations specific to 
the various subtypes of RCC will be targeted. It is 
likely that in the not too distant future, a patient with 
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metastatic RCC will undergo a pre-treatment percu-
taneous renal biopsy enabling us to not only identify 
the histologic tumor type but rather develop a tissue 
microarray identifying the specific genetic altera-
tions in an individual patient’s tumor which can then 
be targeted using a selective treatment combination 
and enabling a more personalized and highly effec-
tive therapeutic approach to be initiated.
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